Abstract
Purpose Pharmacogenetic information regarding the Mexican-American population is sparse. It has been suggested that fewer Mexican-Americans are CYP2D6 poor metabolizers than Anglos. While some studies have reported that U.S. Hispanics are more sensitive to drugs metabolized by CYP2D6 others have not shown differences. Our ongoing study investigates the pharmacogenetics of desipramine or fluoxetine in the in the Los Angeles Mexican-origin population. Methods: Subanalysis of a prospective, double-blind, placebo-controlled study. Results: We describe two Mexican-American women who were found to have elevated levels of desipramine and severe side effects after taking a minimal dose for two weeks. CYP2D6 genotyping indicated both women to have the mutant allele *4/*4 which has been found in poor metabolizers. Conclusions: CYP2D6 genotyping is of considerable public health relevance. This should become a routine laboratory exam for patients who are treated with medications that are metabolized by this enzyme, including minorities whose adverse responses are at times inappropriately attributed to cultural factors. Clinical Pharmacology & Therapeutics (2004) 75, P41–P41; doi: 10.1016/j.clpt.2003.11.153
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
